医学
彭布罗利珠单抗
子宫内膜癌
卡铂
肿瘤科
伦瓦提尼
内科学
紫杉醇
癌症
化疗
回顾性队列研究
重症监护医学
免疫疗法
顺铂
甲状腺癌
作者
Maria M. Rubinstein,Sherry Shen,Bradley J. Monk,David S.P. Tan,Angélica Nogueira-Rodrigues,Daisuke Aoki,Jalid Sehouli,Vicky Makker
标识
DOI:10.1016/j.ygyno.2022.10.012
摘要
Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, "platinum sensitivity" in endometrial cancer is subjective and largely based on expert opinion and/or practitioner experience. Small retrospective studies have tried to provide guidance on the utility of platinum rechallenge, but they are limited by variable patient characteristics and small sample sizes. The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions.
科研通智能强力驱动
Strongly Powered by AbleSci AI